autologous cytokine-induced killer cells/vaccinia virus DD-CDSR CRX100

A preparation of autologous cytokine-induced killer (CIK) cells that have been generated ex vivo from killer cells treated with cytokines and infected with the oncolytic vaccinia virus DD-CDSR (vvDD-CDSR; double-deleted vaccinia virus plus CD/SMR), with potential immunomodulatory and antineoplastic activities. CIK cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes. Upon infusion of autologous CIK cells/vvDD-CDSR CRX100, the CIK cells protect the oncolytic virus vvDD-CDSR from immune attack and enhance the delivery of the oncolytic virus to tumor cells. The oncolytic virus vvDD-CDSR preferentially targets and infects tumor cells causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells.